TY - JOUR
T1 - Fractal motor activity regulation and sex differences in preclinical Alzheimer's disease pathology
AU - Gao, Lei
AU - Li, Peng
AU - Gaba, Arlen
AU - Musiek, Erik
AU - Ju, Yo El S.
AU - Hu, Kun
N1 - Funding Information:
The authors acknowledge the contributions of the investigators, participants, and funding support for the Knight Alzheimer's Disease Research Center. Research reported in this publication was supported by National Institutes of Health awards T32GM007592 and R03AG067985 (Gao); K08NS079405 (Musiek); K23NS089922, UL1RR024992 and subaward KL2-TR000450 (Ju); RF1AG059867, RF1AG064312, and R01AG048108 (Hu); and P50AG05681, P01AG03991, and P01AG026276 (Knight Alzheimer's Disease Research Center); support also came from the BrightFocus Foundation A2020886S (Li) and the Foundation of Anesthesia Education and Research (Gao).
Funding Information:
The authors acknowledge the contributions of the investigators, participants, and funding support for the Knight Alzheimer's Disease Research Center. Research reported in this publication was supported by National Institutes of Health awards T32GM007592 and R03AG067985 (Gao); K08NS079405 (Musiek); K23NS089922, UL1RR024992 and subaward KL2‐TR000450 (Ju); RF1AG059867, RF1AG064312, and R01AG048108 (Hu); and P50AG05681, P01AG03991, and P01AG026276 (Knight Alzheimer's Disease Research Center); support also came from the BrightFocus Foundation A2020886S (Li) and the Foundation of Anesthesia Education and Research (Gao).
Publisher Copyright:
© 2021 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association
PY - 2021
Y1 - 2021
N2 - Introduction: Degradation in fractal motor activity regulation (FMAR), a measure of multiscale self-similarity of motor control, occurs in aging and accelerates with clinical progression to Alzheimer's disease (AD). Whether FMAR changes occur during the pre-symptomatic phase of the disease in women and men remains unknown. Methods: FMAR was assessed in cognitively normal participants (n = 178) who underwent 7 to 14 days of home actigraphy. Preclinical AD pathology was determined by amyloid imaging-Pittsburgh compound B (PiB) and cerebrospinal fluid (CSF) phosphorylated-tau181 (p-tau) to amyloid beta 42 (Aβ42) ratio. Results: Degradation in daytime FMAR was overall significantly associated with preclinical amyloid plaque pathology via PiB+ imaging (beta coefficient β = 0.217, standard error [SE] = 0.101, P =.034) and increasing CSF tau181-Aβ42 ratio (β = 0.220, SE = 0.084, P =.009). In subset analysis by sex, the effect sizes were significant in women for PiB+ (β = 0.279, SE = 0.112, P =.015) and CSF (β = 0.245, SE = 0.094, P =.011) but not in men (both Ps >.05). These associations remained after inclusion of daily activity level, apolipoprotein E ε4 carrier status, and rest/activity patterns. Discussion: Changes in daytime FMAR from actigraphy appear to be present in women early in preclinical AD. This may be a combination of earlier pathology changes in females reflected in daytime FMAR, and a relatively underpowered male group. Further studies are warranted to test FMAR as an early noncognitive physiological biomarker that precedes the onset of cognitive symptoms.
AB - Introduction: Degradation in fractal motor activity regulation (FMAR), a measure of multiscale self-similarity of motor control, occurs in aging and accelerates with clinical progression to Alzheimer's disease (AD). Whether FMAR changes occur during the pre-symptomatic phase of the disease in women and men remains unknown. Methods: FMAR was assessed in cognitively normal participants (n = 178) who underwent 7 to 14 days of home actigraphy. Preclinical AD pathology was determined by amyloid imaging-Pittsburgh compound B (PiB) and cerebrospinal fluid (CSF) phosphorylated-tau181 (p-tau) to amyloid beta 42 (Aβ42) ratio. Results: Degradation in daytime FMAR was overall significantly associated with preclinical amyloid plaque pathology via PiB+ imaging (beta coefficient β = 0.217, standard error [SE] = 0.101, P =.034) and increasing CSF tau181-Aβ42 ratio (β = 0.220, SE = 0.084, P =.009). In subset analysis by sex, the effect sizes were significant in women for PiB+ (β = 0.279, SE = 0.112, P =.015) and CSF (β = 0.245, SE = 0.094, P =.011) but not in men (both Ps >.05). These associations remained after inclusion of daily activity level, apolipoprotein E ε4 carrier status, and rest/activity patterns. Discussion: Changes in daytime FMAR from actigraphy appear to be present in women early in preclinical AD. This may be a combination of earlier pathology changes in females reflected in daytime FMAR, and a relatively underpowered male group. Further studies are warranted to test FMAR as an early noncognitive physiological biomarker that precedes the onset of cognitive symptoms.
KW - Pittsburgh compound B
KW - actigraphy
KW - amyloid beta 42
KW - amyloid plaque pathology
KW - amyloid positron emission tomography imaging
KW - fractal regulation
KW - interdaily stability
KW - intradaily variability
KW - phosphorylated tau
KW - preclinical Alzheimer's disease
KW - sex differences
UR - http://www.scopus.com/inward/record.url?scp=85123703799&partnerID=8YFLogxK
U2 - 10.1002/dad2.12211
DO - 10.1002/dad2.12211
M3 - Article
C2 - 34189248
AN - SCOPUS:85123703799
SN - 2352-8729
VL - 13
JO - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
JF - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
IS - 1
M1 - e12211
ER -